Phosphoramidon

Summary

Phosphoramidon is a naturally occurring pseudopeptide antibiotic/inhibitor isolated from Streptomyces tanashiensis. It is a classical pharmacological tool compound used extensively in research to characterize zinc metalloprotease activity, particularly neprilysin and endothelin-converting enzyme. It is not approved for clinical use and is used primarily as a reference inhibitor in biochemical and pharmacological studies.

Mechanism of Action

Potent inhibitor of zinc metalloprotease enzymes, particularly thermolysin, neprilysin (neutral endopeptidase, NEP), and endothelin-converting enzyme (ECE). Coordinates with the active-site zinc ion via its phosphoramidon moiety, blocking substrate access and enzymatic cleavage of peptide bonds.

Routes of Administration

Goals & Uses

• Inhibition of endothelin-converting enzyme (ECE)Research / Pharmacological ToolHigh
• Inhibition of neprilysin (NEP) activityResearch / Pharmacological ToolHigh
• Study of enkephalin and atrial natriuretic peptide metabolismNeuropharmacology / Cardiovascular ResearchModerate
• Characterization of thermolysin activityBiochemical ResearchHigh

Contraindications

• Human therapeutic administrationClinical UseHigh

Adverse Effects

• Broad metalloprotease inhibitionOff Target EffectsUnknown
• Cardiovascular effects (in vivo animal studies)CardiovascularUnknown

Drug Interactions

• Neprilysin substrates (ANP, BNP, enkephalins)Low
• Endothelin receptor antagonistsLow

Population Constraints

• Human useGeneral PopulationAbsolute

Regulatory Status

• European UnionUnapprovedResearch use only; no EMA authorization.
• United StatesUnapprovedResearch tool compound only; not an FDA-regulated drug for human use.
• United KingdomUnapprovedResearch use only; no MHRA authorization.

Not approved by any regulatory authority (FDA, EMA, MHRA) for human therapeutic use. Used exclusively as a research/tool compound in laboratory settings.

Evidence & Sources

No sources recorded yet.